NervGen Pharma Corp. Common stock
NGENAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Apr 8, 2026 | Maxim Group | $12.00(+187%) | $4.18 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Jul 14, 2026 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.10| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.37 | $-0.06 | — | $4.5K |
| May 18, 2026 | $-0.01 | $-0.07 | — | $4.5K |
| Apr 2, 2026 | $-0.26 | $-0.06 | — | $4.5K |
| Nov 25, 2025 | $-0.04 | $-0.06 | — | — |
| Aug 27, 2025 | $-0.09 | $-0.05 | — | — |
| May 15, 2025 | $-0.04 | $-0.06 | — | — |
| Apr 3, 2025 | $-0.10 | $-0.06 | — | — |
| Nov 14, 2024 | $-0.11 | $-0.05 | — | — |
News
NervGen Pharma Corp. is executing the Phase 3 RESTORE trial for NVG-291, targeting functional recovery in chronic spinal cord injury. RESTORE is powered to detect a 2.5-point treatment effect, with no interim efficacy analysis planned, making the outcome binary until topline results. NGEN is funded through the RESTORE topline readout in 1H 2028, but dilution risk remains due to a significant increase in share count and an unused $50M ATM facility.
NervGen Pharma Corp. (NGEN) Discusses Challenges and Advances in Drug and Therapy Trials for Spinal Cord Injury Transcript
VANCOUVER, British Columbia, Sept. 25, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced it will restate its audited annual financial statements for the year ended December 31, 2025, and its unaudited interim financial statements for the quarter ended June 30, 2026.
VANCOUVER, British Columbia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that it will host its inaugural R&D Day webcast on Wednesday, September 30, 2026, from 10:00 a.m. to 12:00 p.m. ET.
VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today reported financial results for the second quarter ended June 30, 2026, and provided business updates.